Yuhan Corporation (KRX:000100)

Market Cap	6.05T -30.0%
Revenue (ttm)	2.19T +5.7%
Net Income	191.09B +174.6%
EPS	2,559.43 +171.4%
Shares Out	74.44M
PE Ratio	31.84
Forward PE	42.96
Dividend	600.00 (0.72%)
Ex-Dividend Date	Feb 26, 2026

Volume	265,516
Average Volume	286,203
Open	82,500
Previous Close	81,500
Day's Range	81,700 - 84,600
52-Week Range	80,000 - 136,400
Beta	0.46
RSI	30.65
Earnings Date	Aug 14, 2026

About Yuhan

Yuhan Corporation, a pharmaceutical company, engages in the research, development, and production of active pharmaceutical products and intermediates in South Korea and internationally. It offers antivirals, antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds; Revanex, an acid pump antagonist for the treatment of peptic ulcers and gastritis-related mucosal injury; ETC products in the areas of cardiovascular, alimentary, genito-urinary, metabolic, respiratory and allergy, and neuro sy...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1926
• Country: South Korea
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 000100

Financial Performance

In 2025, Yuhan's revenue was 2.19 trillion, an increase of 5.75% compared to the previous year's 2.07 trillion. Earnings were 191.09 billion, an increase of 170.33%.